Articles related to CLINICAL TRIALS

The I-WOTCH trial offers insightful findings on multimodal interventions for opioid-dependent chronic pain patients. Read on for a detailed examination of the trial’s significant impact on patient wellbeing and opioid cessation.

Promising Discovery: Existing Drugs Could Be Repurposed for First Treatment of Dementia-Linked Strokes Clinical trials reveal the potential of two commonly used cardiac drugs, isosorbide mononitrate and cilostazol, to serve as novel treatment options for lacunar strokes, a leading cause of dementia. Key Points: “Now we understand more about what is triggering these small vessel strokes to attack the brain, we’ve been able to focus our efforts on treatments that can put a halt to this damage…as these drugs are already widely available for other circulatory disorders, and inexpensive, it shouldn’t take too long to move our findings from research into everyday clinical practice.” Professor Joanna Wardlaw of the University of Edinburgh and UK Dementia Research Institute

Addressing the Crisis: Reinventing the Clinical Research Workforce The clinical research enterprise, the backbone of medical advancement, is at a crossroads. A deep-seated crisis in the workforce threatens to halt progress, demanding urgent, systemic solutions. Key Points: “Now is the time to fix the evidence generation system.” US Food and Drug Administration (FDA) Commissioner Robert M. Califf in January 2023

Neoadjuvant Chemotherapy and Upfront Surgery: A Comparative Study in Resectable Pancreatic Cancer In a recent study presented at the 2023 ASCO Annual Meeting, researchers found no significant survival benefit of neoadjuvant chemotherapy over upfront surgery in patients with resectable pancreatic cancer. Key Points: “Results of this trial do not support neoadjuvant FOLFIRINOX as standard of care in resectable pancreatic cancer.” Knut Jørgen Labori, MD, PhD, Oslo University Hospital, Norway

Roswell Park Comprehensive Cancer Center Shines at ASCO 2023 Roswell Park Comprehensive Cancer Center recently showcased a series of groundbreaking research studies at the American Society of Clinical Research (ASCO) 2023 meeting, highlighting their commitment to advancing cancer management and clinical trials. “This study has revealed differences in transcriptional metabolic profiles and other drivers of disease, as well as immune profiles, between younger and older CRC populations. This biology should be explored in the future, as new avenues for treatment in younger CRC populations.” Dr. Deepak Vadehra from the “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients” study

Pivotal Role of Adjuvant Osimertinib in EGFR-Mutated NSCLC Survival A groundbreaking phase 3 trial reveals the significant impact of adjuvant osimertinib on overall survival rates in patients with resected, EGFR-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC). “Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.” ADAURA ClinicalTrials.gov number, NCT02511106